BNP Paribas Arbitrage SNC Acquires 53,184 Shares of IQVIA Holdings Inc. (NYSE:IQV)

BNP Paribas Arbitrage SNC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 84.6% in the 2nd quarter, Holdings Channel.com reports. The fund owned 116,050 shares of the medical research company’s stock after acquiring an additional 53,184 shares during the quarter. BNP Paribas Arbitrage SNC’s holdings in IQVIA were worth $26,085,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Mutual Advisors LLC increased its stake in shares of IQVIA by 3.1% during the second quarter. Mutual Advisors LLC now owns 1,602 shares of the medical research company’s stock worth $360,000 after purchasing an additional 48 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in IQVIA by 1.1% in the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 5,034 shares of the medical research company’s stock valued at $1,131,000 after purchasing an additional 55 shares during the last quarter. Penserra Capital Management LLC boosted its holdings in IQVIA by 6.1% in the 4th quarter. Penserra Capital Management LLC now owns 971 shares of the medical research company’s stock valued at $198,000 after purchasing an additional 56 shares during the last quarter. Byrne Asset Management LLC boosted its holdings in IQVIA by 0.8% in the 2nd quarter. Byrne Asset Management LLC now owns 6,709 shares of the medical research company’s stock valued at $1,508,000 after purchasing an additional 56 shares during the last quarter. Finally, Glassman Wealth Services boosted its holdings in IQVIA by 21.3% in the 2nd quarter. Glassman Wealth Services now owns 342 shares of the medical research company’s stock valued at $77,000 after purchasing an additional 60 shares during the last quarter. 86.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on IQV shares. Barclays reduced their price target on shares of IQVIA from $245.00 to $215.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. Citigroup boosted their price target on shares of IQVIA from $200.00 to $225.00 and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Truist Financial reduced their price target on shares of IQVIA from $260.00 to $240.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. HSBC started coverage on shares of IQVIA in a research note on Wednesday, September 6th. They issued a “buy” rating and a $260.00 price target on the stock. Finally, Morgan Stanley reduced their price target on shares of IQVIA from $240.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, November 3rd. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $236.57.

IQVIA Trading Up 2.7 %

Shares of IQVIA stock opened at $205.87 on Thursday. The company has a fifty day simple moving average of $197.88 and a 200-day simple moving average of $207.02. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $241.86. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 2.12. The stock has a market cap of $37.57 billion, a price-to-earnings ratio of 34.60, a PEG ratio of 2.50 and a beta of 1.42.

Insider Activity

In other news, insider Constantinos Panagos sold 27,317 shares of the company’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $208.67, for a total value of $5,700,238.39. Following the completion of the transaction, the insider now owns 14,250 shares in the company, valued at approximately $2,973,547.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.50% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.